Ascletis Pharma, Inc.HKEX: 1672

Next Day Disclosure Return

Oct 21, 2026 at 5:19 AM EDT · Issued by Ascletis Pharma, Inc. via HKEXnews

Filed with HKEX · Stock code 1672 · Oct 21, 2026 at 5:19 AM EDT

On 6ix: 6ix.com/news/next-day-disclosure-return-1350

View Attachment

6ix is reading this filing.

View original source (HKEXnews)Ascletis Pharma, Inc. on 6ix

Earlier from Ascletis Pharma

Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesityOct 20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 6
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026Oct 2

Later from Ascletis Pharma

Voluntary announcement - ascletis' strategic partner sagimet announces first patient dosed in phase iii U.S. clinical trial of denifanstat (ASC40) for moderate to severe acneOct 23

All Ascletis Pharma news releases

Follow Ascletis Pharma into a list and get an email when it puts out news.

Follow Ascletis Pharma